• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Competitive Technologies Expands Relationship With Medical College of Georgia Research Institute to Commercialize Innovative Therapeutic Technologies

Posted on: Friday, 12 January 2007, 09:00 CST

Competitive Technologies, Inc. (AMEX: CTT) today announced that it has signed an exclusive, worldwide service and representation agreement with the Medical College of Georgia Research Institute to commercialize a family of novel therapeutic technologies.

"We are pleased to expand our relationship with the Medical College of Georgia Research Institute in representing these technologies for commercialization," stated Kevin Drumm, Business Development Executive for Competitive Technologies, Inc. "We have worked closely with the Medical College of Georgia in identifying novel technologies which are in strategic areas of interest for CTT's clients in the pharmaceutical industry. These therapeutics are in the important fields of neuroprotection, cognitive enhancement, osteoporosis, pain management, chemoprevention and autoimmune treatments."

"We are thrilled to expand our relationship with the Medical College of Georgia. This therapeutic portfolio strengthens and is synergistic to our life sciences offerings," commented D.J. Freed, Ph.D., President and Chief Executive Officer of Competitive Technologies. Dr. Freed continued, "We have been aggressively adding to our portfolio of licensable technologies at the rate of two to three per month for the last year and a half and have many more in negotiations. The continued expansion of our technology inventory is a key component of our strategic plan and we believe increasing our pipeline of available technologies is critical to achieving success for our clients and shareholders. We are making important strides towards reaching this goal."

About Medical College of Georgia

The Medical College of Georgia (MCG), the state's premier academic health sciences university, has much to offer the corporate sector. With a rapidly expanding research program (with special emphasis in cardiovascular disease, neurological disease, cancer, infection and inflammation, and diabetes and obesity), it offers numerous opportunities for licensing and for conducting joint research projects. The MCG Office of Technology Transfer and Economic Development, which orchestrated the license with Competitive Technologies, is a main point of entry for corporations wishing to work with the medical program based in Augusta, Georgia. MCG is involved in nearly 400 different funded research activities and related studies in its Schools of Allied Health Sciences, Dentistry, Graduate Studies, Medicine and Nursing. Research is carried out both in basic and clinical disciplines. For more information, please visit http://www.mcg.edu/research/techtransfer.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider, focused on bringing the intellectual property assets of its clients to the marketplace. CTT specializes in identifying, developing and commercializing innovative technologies in a variety of areas, including life and physical sciences, electronics, and nanotechnologies. Through its global distribution platform, CTT maximizes the value of its clients' intellectual property assets. For more information, please visit: www.competitivetech.net.

Statements about our future expectations, including development and regulatory plans, and all other statements in this press release, other than historical facts, are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. If and when used herein, the words "may,""will,""should,""anticipate,""believe,""appear,""intend,""plan,""expect,""estimate,""approximate," and similar expressions, as they relate to us or our business or management, are intended to identify such forward-looking statements. These statements involve risks and uncertainties related to our ability to obtain rights to market technologies, market acceptance of and competition for our licensed technologies, growth strategies and strategic plans, operating performance and financing of our operations, industry trends, and other risks and uncertainties inherent in our business, including those set forth in Item 1A under the caption "Risk Factors," in our most recent Annual Report on Form 10-K for the year ended July 31, 2006, filed with the Securities and Exchange Commission ("SEC") on October 30, 2006, and other factors that may be described in our other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

Source: Business Wire

More News in this Category